IDEAYA Biosciences
Stock Forecast, Prediction & Price Target
IDEAYA Biosciences (IDYA) stock Price Target by analysts
$44
Potential upside: 86.59%
IDEAYA Biosciences price prediction
What is IDEAYA Biosciences stock analysts` prediction?
IDEAYA Biosciences stock forecast: Based on 3 Wall Street analysts` predicted price targets for IDEAYA Biosciences in the last 3 months, the avarage price target is $44, with a high forecast of $NaN. The average price target represents a 86.59% change from the last price of $23.58.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
IDEAYA Biosciences stock Price Target by analysts
Full breakdown of analysts given IDEAYA Biosciences price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Andrew Berens Leerink Partners | 0% 0/1 | 11 months ago | $27 14.50% upside | $29.58 | StreetInsider | Previous targets (0) |
David Dai UBS | 0% 0/1 | 11 months ago | $50 112.04% upside | $29.5 | StreetInsider | Previous targets (0) |
Graig Suvannavejh Mizuho Securities | 0% 0/2 | about 1 year ago | $55 133.24% upside | $31.37 | StreetInsider | Previous targets (1) |
Corinne Jenkins Goldman Sachs | 0% 0/1 | about 1 year ago | $48 103.56% upside | $33.73 | StreetInsider | Previous targets (0) |
Justin Zelin BTIG | 0% 0/1 | about 1 year ago | $62 162.93% upside | $33.87 | StreetInsider | Previous targets (0) |
Ben Burnett Stifel Nicolaus | 0% 0/3 | about 1 year ago | $66 179.89% upside | $33.73 | StreetInsider | Previous targets (2) |
Ben Burnett Stifel Nicolaus | 0% 0/3 | about 1 year ago | $68 188.37% upside | $36.97 | StreetInsider | Previous targets (2) |
Yigal Nochomovitz Citigroup | 0% 0/1 | about 1 year ago | $58 145.97% upside | $39.8 | TheFly | Previous targets (0) |
Matthew Biegler Oppenheimer | 0% 0/1 | about 1 year ago | $53 124.76% upside | $35.86 | StreetInsider | Previous targets (0) |
Gregory Renza RBC Capital | 0% 0/1 | about 1 year ago | $61 158.69% upside | $37.33 | TheFly | Previous targets (0) |
Graig Suvannavejh Mizuho Securities | 0% 0/2 | about 1 year ago | $50 112.04% upside | $40.2 | StreetInsider | Previous targets (1) |
Ben Burnett Stifel Nicolaus | 0% 0/3 | over 1 year ago | $63 167.17% upside | $38.89 | StreetInsider | Previous targets (2) |
Unknown Capital One Financial | N/A | over 2 years ago | $29 22.98% upside | $17.47 | Benzinga | N/A |
Unknown Guggenheim | N/A | about 3 years ago | $32 35.70% upside | $12.4 | Benzinga | N/A |
Unknown Oppenheimer | N/A | about 3 years ago | $20 -15.18% downside | $9.83 | Benzinga | N/A |
Unknown Robert W. Baird | N/A | about 3 years ago | $18 -23.66% downside | $10.74 | Benzinga | N/A |
IDEAYA Biosciences Financial Estimates
IDEAYA Biosciences Revenue Estimates
IDEAYA Biosciences EBITDA Estimates
IDEAYA Biosciences Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $27.94M N/A | $50.93M 82.28% | $23.38M -54.08% | Avg: $104.62M Low: $51.93M High: $199.00M avg. 347.41% | Avg: $87.32M Low: $41.41M High: $153.37M avg. -16.54% | Avg: $275.66M Low: $130.73M High: $484.18M avg. 215.69% | Avg: $679.43M Low: $322.21M High: $1.19B avg. 146.46% |
Net Income
% change YoY
| $-47.53M N/A | $-54.80M -15.31% | $-112.96M -106.10% | Avg: $-131.88M Low: $-182.91M High: $333.99M avg. -16.74% | Avg: $-170.21M Low: $-189.24M High: $-45.44M avg. -29.06% | Avg: $-33.21M Low: $-65.88M High: $-10.51M avg. 80.48% | Avg: $173.13M Low: $54.79M High: $343.38M avg. 621.21% |
EBITDA
% change YoY
| $-50.26M N/A | $-62.50M -24.33% | $-130.42M -108.66% | Avg: $-62.77M Low: $-119.40M High: $-31.15M avg. 51.86% | Avg: $-52.39M Low: $-92.02M High: $-24.84M avg. 16.54% | Avg: $-165.40M Low: $-290.51M High: $-78.44M avg. -215.69% | Avg: $-407.65M Low: $-716.01M High: $-193.32M avg. -146.46% |
EPS
% change YoY
| -$1.35 N/A | -$1.32 2.22% | -$1.96 -48.48% | Avg: -$1.8 Low: -$3.18 High: $5.81 avg. 8.08% | Avg: -$2.12 Low: -$3.29 High: -$0.79 avg. -17.44% | Avg: -$0.58 Low: -$1.15 High: -$0.18 avg. 72.70% | Avg: $3.01 Low: $0.95 High: $5.97 avg. 621.21% |
Operating Expenses
% change YoY
| $78.20M N/A | $113.43M 45.03% | $157.81M 39.12% | Avg: $87.35M Low: $43.35M High: $166.14M avg. -44.64% | Avg: $72.90M Low: $34.57M High: $128.04M avg. -16.54% | Avg: $230.15M Low: $109.14M High: $404.24M avg. 215.69% | Avg: $567.24M Low: $269.01M High: $996.31M avg. 146.46% |
FAQ
What is IDEAYA Biosciences stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 163.97% in 2025-2028.
We have gathered data from 9 analysts. Their low estimate is -182.91M, average is -131.88M and high is 333.99M.
What is IDEAYA Biosciences stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 173.25% in 2025-2028.
We have gathered data from 7 analysts. Their low revenue estimate is $51.93M, average is $104.62M and high is $199.00M.
What is IDEAYA Biosciences stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 171.14% in 2025-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is -$3.18, average is -$1.8 and high is $5.80.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering IDEAYA Biosciences stock. The most successful analyst is Andrew Berens.